Topic: Catherine Arnold
NEW YORK/LONDON (Reuters) - Bristol-Myers Squibb Co's shares rose more than 8 percent on Monday after news over the weekend that its experimental drug ipilimumab extended survival in patients with deadly skin cancer.Bristol's ipilimumab added an average of four ...
Investors snapped up shares of Merck & Co. Wednesday after a Credit Suisse analyst said the stock could rise as Wall Street takes a closer look at the drugmaker's pipeline. Catherine Arnold upgraded the shares to "Outperform" from "Neutral," and raised her ...
Merck shares rose 3.7% yesterday; the WSJ, among others, cite Credit Suisse analyst Catherine Arnold's decision to raise her rating on the stock to " So what did Arnold say in the note that apparently added a few billion to Merck ...
AstraZeneca will reveal the complete data from this head-to-head comparison between Brilinta, its experimental anti-platelet, anti-clotting drug, and Bristol-Myers's multi-billion-dollar blockbuster Plavix. In May, AZ announced that Brilinta was statistically superior to Plavix in preventing cardiovascular events in patients with acute ...
An FDA advisory committee just voted 15-2 that the benefits of the experimental anticlotting drug rivaroxaban outweigh the risks, Dow Jones Newswires reports. And, as we noted this morning, the FDA doesn't always follow the advice of its advisory committees. The ...
Co. and partner Schering-Plough Corp. both posted fourth-quarter results Tuesday that topped analysts' expectations, sending their shares up, but revenues from their crucial cholesterol franchise plunged.Both companies beat profit expectations primarily due to aggressive cost-cutting, including eliminating thousands of jobs under ...
In the multi-billion dollar deals game that is pharma's answer to the NCAA tournament, GlaxoSmithKline, Novartis, Bristol-Myers Squibb, AstraZeneca, Sanofi-Aventis and Wyeth could all see action soon, according to a report out this morning from analyst Catherine Arnold at Credit Suisse ...
After the closing bell Monday, Eli Lilly (LLY) and Amylin Pharmaceuticals (AMLN) announced that they're going to hold a conference call for analysts and investors about their diabetes drug Byetta.. Credit Suisse big pharma analyst Catherine Arnold put out a research ...
Aranesp and Procrit (also known as Epogen) increase the risk of death for cancer patients, according to an analysis published in the current issue of JAMA.. "These risks have been previously defined," Roger Perlmutter, Amgen's executive vice president of research and ...
In a turbulent market, pharma stocks are a good way to play defense. "In 2008, the U.S. Major Pharmaceutical sector could provide a defensive choice in regards to relative growth and low debt exposure," Credit Suisse analyst Catherine Arnold wrote last ...
Video Gallery
-
Catherine Arnold singing "Somewhere that's ...
Catherine singing "Somewhere that's Green" from Little Shop of ...2009-11-04 -
Meet the Author - Catherine Arnold
The BBC's Meet the Author talks to Catherine Arnold ...2010-07-28 -
Credit Suisse's Catherine Arnold on ...
Pfizer reaches a deal to buy rival drugmaker Wyeth, reports ...2009-02-18
